Table 1.

Data about efficacy and safety of mAb-based treatments in NTE NDMM patients.

a. Efficacy
Trial	N pts	Treatment	OR (%)	CR/VGPR (%)	MRD neg (%)	mPFS [95% CI] (Months)	mOS [95% CI] (Months)
ALCYONE [38]	706	Dara-VMP	90.9	43/71	28	36.4	78.0
		vs.	vs.	vs.	vs.	vs.	vs.
		VMP	73.9	25/50	7	19.3	67.9
MAIA [16,39]	737	Dara-Rd	93	50/81	24.2	NR	NR
		vs.	vs.	vs.	vs.	vs.	vs.
		Rd	82	27/55	7.3	33.8	NR
HOVON 143 [28]	46	Dara-Ixa-dex			-	9-month PFS rates:	9-month OS rates:
		interm.-fit	87	0/39		78 (55–90)	100
		vs.	vs.	vs.		vs.	vs.
		frail pts	78	4/26		61 (38–77)	83 (60–93)
SWOG-1211 [40]	103	Elo-VRd	-	-	-	31	68
		vs.				vs.	vs.
		VRd				34	NR
TCD13983 [41,42,43]	44	Isa-VRd	100	41/52	30.8	NR	-
		vs.	vs.	vs.	vs.	vs.
		Isa-VCd	93.3	59	33.3	NR
b. Safety
Trial	N pts	Treatment	Total Discontinuation (%)	Discontinuation due to AE (%)	Discontinuation due to Death (%)	Grade 3–4 Hematologic Toxicities: Neutropenia/Anemia (%)	Grade 3–4 Non-Hematologic Toxicities: Infections (%)
ALCYONE [38]	706	Dara-VMP	-	7	24	40/15	22
		vs.		vs.	vs.	vs.	vs.
		VMP		9	36	39/20	15
MAIA [16,39]	737	Dara-Rd	39	9	23	51/14	36
		vs.	vs.	vs.	vs.	vs.	vs.
		Rd	64	18	28	35.3/21	27
HOVON 143 [28]	46	Dara-Ixa-dex
		Interm.-fit	30	4	0	8/-	9
		vs.	vs.	vs.	vs.	vs.	vs.
		frail pts	39	0	13	17/-	9
SWOG-1211 [40]	103	Elo-VRd	-	-	-	-	16
		vs.					vs.
		VRd					8
TCD13983 [41,42,43]	22	Isa-VRd	14	9	5	12.5%	27

Abbreviations: NTE, transplant ineligible; NDMM, newly diagnosed multiple myeloma; ORR, overall response rate; CR, complete response; VGPR, very good partial response; MRD, minimal residual disease; neg, negativity; mPFS, median progression-free survival; mOS, median overall survival; NR, not reached, AE, adverse event; CI, confidence interval; Dara, daratumumab; V, bortezomib; M, melphalan; P, prednisone; R, lenalidomide; d, dexamethasone; Ixa, ixazomib; Elo, elotuzumab; Isa, isatuximab; C, cyclophosphamide; interm.-fit, intermediate fit; N, number; pts, patients.